Protara Therapeutics Q1 2025 net loss $11.9M; TARA-002 100% CR in BCG-Unresponsive cohort

Protara Therapeutics, Inc.

Cash, cash equivalents and investments total $157.5M as of Mar 31, 2025; expected to fund operations into 2027.
TARA-002 in BCG-Unresponsive NMIBC: 100% complete response (CR) at any time (5/5), 67% CR at 12 months (2/3) as of Apr 16, 2025.
Interim results from ~25 six-month evaluable BCG-Unresponsive patients expected by end of 2025; THRIVE-3 trial of IV Choline Chloride to start Q3 2025.
Appointed Leonardo Viana Nicacio, M.D., as CMO and Shane Williams, Ph.D., as VP, Head of HR/Chief People Officer in April 2025.
Net loss $11.9M ($0.29/sh) vs $11.1M ($0.97/sh) in Q1 2024; R&D expenses rose to $9.1M from $7.7M, G&A to $5.0M from $4.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.